Psychological Distress Reported for Indolent Non-Hodgkin Lymphomas
TUESDAY, Nov. 21, 2023 -- Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.Richard A. Newcomb, M.D., from Massachusetts General Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2023 Category: Pharmaceuticals Source Type: news
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL
(MedPage Today) -- Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the phase III randomized PREVAPIX... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2023 Category: Cardiology Source Type: news
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Was This a Recurrence of Non-Hodgkin ’s Lymphoma or Something Else?
“Go to the emergency room,” the doctor told him after hearing of his trip and fever, rash and whole-body weakness. “You need to be seen.” (Source: NYT Health)
Source: NYT Health - November 20, 2023 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Chikungunya Virus Non-Hodgkin ' s Lymphoma Lyme Disease Joints (Body Part) Source Type: news
FDA Panel Voices Concerns Over Two Lymphoma Rushed Approvals FDA Panel Voices Concerns Over Two Lymphoma Rushed Approvals
' The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway. 'MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent'
(MedPage Today) -- An unprecedented wait for final FDA approval will drag on for two orphan lymphoma drugs, at least a little while longer, as the agency decides how to end the delays and prevent them from happening again.
The dihydrofolate reductase... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 17, 2023 Category: American Health Source Type: news
Road to RSNA 2023: Molecular Imaging
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotrac...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 2023 Molecular Imaging Preview Source Type: news
Does contrast media used with PET/MRI make a difference?
Thursday, November 30 | 8:20 a.m.-8:30 a.m. | R1-SSNMMI07-3 | Room S403AFindings presented during this session suggest that the use of MRI contrast agents during PET/MRI exams has no additional positive benefit for primary and follow-up staging of pediatric lymphoma patients.Presenter Nils-Martin Bruckmann, MD, of Heinrich Heine University Düsseldorf in Germany, will discuss a study that evaluated the influence of an MRI contrast agent on primary and follow-up staging in 32 pediatric patients with newly diagnosed lymphoma using F-18 FDG-PET/MRI.Out of 105 total exams analyzed on a patient-based level, FDG PET/MRI scans us...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Lymphoma Drug Copanlisib to Be Pulled From U.S. Market
(MedPage Today) -- Bayer announced plans to pull its follicular lymphoma drug copanlisib (Aliqopa) from the U.S. market following a failed confirmatory study and discussions with the FDA.
In that phase III study (CHRONOS-4) -- required as a... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 14, 2023 Category: American Health Source Type: news
Follicular Lymphoma Drug Withdrawn After Further Trial Fails Follicular Lymphoma Drug Withdrawn After Further Trial Fails
Bayer on Monday said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the US market.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2023 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
EXCLUSIVE: I thought I'd pulled a muscle, it turned out to be a grapefruit-sized cancerous TUMOR
Jaclyn Downs felt a slight ache in her chest and assumed she'd pulled a muscle while exercising. In fact, a large lymphoma had been growing for months (Source: the Mail online | Health)
Source: the Mail online | Health - November 12, 2023 Category: Consumer Health News Source Type: news
Shuckin' Shack Raises $80K for the Leukemia and Lymphoma Society with Second Annual Fresh & amp; Raw Tour
The oyster bar nearly doubled its impact compared to its inaugural live music tour in 2022, traveling to 16 cities in just four weeks. WILMINGTON, N.C., Nov. 8, 2023 /PRNewswire-PRWeb/ -- After a month-long community party that spanned 16 cities and 3,500 miles, Shuckin' Shack, the oyster... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 8, 2023 Category: Pharmaceuticals Tags: CSR Source Type: news
How my strange seagull laugh ended up being CANCER
Maddy Elleby, from Farnham in Surrey, first started feeling unwell with a cough while on holiday but brushed her symptoms off as the flu. She was later diagnosed with Hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - November 8, 2023 Category: Consumer Health News Source Type: news
